Grid Oasis
S&P 500NASDAQ 100Dow JonesRussell 2000All StocksSectors & Industries

EW

+ Watchlist+ Portfolio

Edwards Lifesciences Corp.

Regulated industryPhysical productsSells to businessesTags from an AI model reading the company description.
GridBrain

GridBrain — Sign in

GridSentinel

GridSentinel — Sign in

GridAegis

GridAegis — Sign in

Key Metrics

Previous Close
$105.23
52-Week Range
$74.66 – $108.00
Market Cap
$59.73B
P/E (TTM)
60.40
EPS (TTM)
1.72
Dividend Yield
0.00%
Advanced Metrics
Price/Book
5.51
PEG Ratio
2.32
Return on Equity
9.33%
Return on Assets
8.77%
Gross Margin
78.02%
Operating Margin
28.82%
Profit Margin
15.30%
Current Ratio
4.60
Debt/Equity
0.06
Total Debt
$704.50M
Free Cash Flow
$1.15B
Revenue Growth
10.50%
Earnings Growth
6.70%
Enterprise Value
$55.89B

Market Snapshot

About

Edwards Lifesciences Corp. is a global leader in patient-focused medical innovations for structural heart disease and critical care monitoring. The company is best known for its transcatheter aortic valve replacement (TAVR) systems, which provide a minimally invasive alternative to open-heart surgery for patients with aortic stenosis. Edwards also produces surgical heart valves, hemodynamic monitoring systems, and is developing technologies for treating mitral and tricuspid valve diseases. The company's products are used in hospitals worldwide and have transformed the treatment of structural heart disease.